- Home
- RNXT vs CGTX Comparison
RNXT vs CGTX Comparison
Compare RNXT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- CGTX
- Stock Information
- Founded
- RNXT 2012
- CGTX 2007
- Country
- RNXT United States
- CGTX United States
- Employees
- RNXT N/A
- CGTX N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- CGTX Health Care
- Exchange
- RNXT Nasdaq
- CGTX Nasdaq
- Market Cap
- RNXT 44.6M
- CGTX 53.4M
- IPO Year
- RNXT 2021
- CGTX 2021
- Fundamental
- Price
- RNXT $1.28
- CGTX $2.17
- Analyst Decision
- RNXT Strong Buy
- CGTX Strong Buy
- Analyst Count
- RNXT 2
- CGTX 3
- Target Price
- RNXT $7.50
- CGTX $2.83
- AVG Volume (30 Days)
- RNXT 594.5K
- CGTX 8.0M
- Earning Date
- RNXT 11-12-2025
- CGTX 11-12-2025
- Dividend Yield
- RNXT N/A
- CGTX N/A
- EPS Growth
- RNXT N/A
- CGTX N/A
- EPS
- RNXT N/A
- CGTX N/A
- Revenue
- RNXT $662,000.00
- CGTX N/A
- Revenue This Year
- RNXT $2,988.37
- CGTX N/A
- Revenue Next Year
- RNXT $300.60
- CGTX N/A
- P/E Ratio
- RNXT N/A
- CGTX N/A
- Revenue Growth
- RNXT N/A
- CGTX N/A
- 52 Week Low
- RNXT $0.75
- CGTX $0.22
- 52 Week High
- RNXT $1.69
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- RNXT 61.50
- CGTX 52.79
- Support Level
- RNXT $1.06
- CGTX $2.33
- Resistance Level
- RNXT $1.27
- CGTX $2.60
- Average True Range (ATR)
- RNXT 0.10
- CGTX 0.34
- MACD
- RNXT 0.04
- CGTX -0.09
- Stochastic Oscillator
- RNXT 69.64
- CGTX 15.31
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.